Though lung cancer looks promising a partner is now needed.
ApexOnco Front Page
Recent articles
Deteriorating efficacy and a treatment-related death with Zynlonta plus Columvi spook investors.
The latest projects newly into human trials include BNT3212.
But results come from a curated dataset, with no in-trial comparator.
A common mutation comes into play for PRMT5 inhibition.
Investors now have more reasons to doubt Harmoni's ability to back US approval.
Early data with IDE849 look better those with Zai’s zocilurtatug pelitecan.
Tolerability could decide first-line therapy in EGFRm disease.
